Delving into the Latest Updates on Pardoprunox Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Pardoprunox, Pardoprunox hydrochloride (USAN)

+ [4]

Target

5-HT1A receptor x D2 receptor x D3 receptor

Mechanism

5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), D2 receptor agonists(Dopamine D2 receptor agonists), D3 receptor agonists(Dopamine D3 receptor agonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseMouth and Tooth Diseases+ [1]

Active Indication-

Inactive Indication

Aggressive PeriodontitisDyskinesia, Drug-InducedDyskinesias+ [3]

Originator Organization

Solvay SA

Active Organization-

Inactive Organization

Solvay Pharmaceuticals, Inc.Abbott Products LLC

AbbVie, Inc.

+ [1]

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC12H16ClN3O2

InChIKeyNQRIKTDKFHAOKC-UHFFFAOYSA-N

CAS Registry269718-83-4

View All Structures (2)

The Rubens Study:A Multicenter, Randomized, Double-blind, Parallel Group, Placebo and Pramipexole Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration Schedules of Pardoprunox Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease - The Rubens Study

Start Date24 Nov 2008

Sponsor / Collaborator-

100 Clinical Results associated with Pardoprunox Hydrochloride

Login to view more data

100 Translational Medicine associated with Pardoprunox Hydrochloride

Login to view more data

100 Patents (Medical) associated with Pardoprunox Hydrochloride

Login to view more data

16

Literatures (Medical) associated with Pardoprunox Hydrochloride

01 Jan 2018·NeuroepidemiologyQ4 · MEDICINE

Comprehensive Examination of Therapies for Pain in Parkinson’s Disease: A Systematic Review and Meta-Analysis

Q4 · MEDICINE

Review

Author: Vannabouathong, Christopher ; Rizvi, Syed Fayyaz H ; Malik, Suleiman H ; Rana, Abdul Qayyum ; Akhter, Shakib ; Sarfraz, Zainab ; Qureshi, Abdul Rehman ; Rana, Ruqqiyah

Pain in Parkinson’s disease (PD) is a debilitating symptom with a prevalence of 68%, yet is untreated 50% of the time. What is unclear, however, is which treatment is optimal for minimizing pain severity in PD. Thus, the objective of this systematic review and meta-analysis was to investigate the efficacy of a variety of novel, complimentary, and conventional treatments for pain in PD and elucidate which therapy is the most effective. A systematic search was performed using MEDLINE, PsycINFO, Embase, CINAHL, and CENTRAL databases. To identify additional articles, manual searches of reference lists of included trials were also searched. Major neurology conference proceedings occurring between January 2014 and February 2018 were also searched to identify unpublished studies that may be potentially eligible. Twenty-five randomized controlled trials that encompassed medical, surgical, and complementary therapies met our inclusion criteria and exhibited moderate quality evidence. Two reviewers conducted assessments for study eligibility, risk of bias, data extraction, and quality of evidence rating. A conservative random-effects model was used to pool effect estimates of pain severity. The greatest reductions in pain were found with safinamide (Standardized mean difference = –4.83, 95% CI [–5.07 to –4.59], <i>p</i> < 0.0001), followed by cannabinoids and opioids, multidisciplinary team care, catechol-O-methyltransferase inhibitors, and electrical and Chinese therapies. Moderate effects in reducing pain were in pardoprunox and surgery, while the weakest effects were in dopaminergic agonists and miscellaneous therapies. Safinamide is an important adjunct to standard parkinsonian medication for alleviating pain in PD.

01 Aug 2014·Current Opinion in NeurologyQ2 · MEDICINE

Treatment of early Parkinson's disease

Q2 · MEDICINE

Review

Author: Lyons, Kelly E. ; Pahwa, Rajesh

PURPOSE OF REVIEWThis review summarizes currently available treatment options and treatment strategies, investigational treatments, and the importance of exercise for early Parkinson's disease.RECENT FINDINGSThe available treatment options for early Parkinson's disease have changed little in the past decade and include carbidopa/levodopa, dopamine agonists, and monoamine oxidase type B (MAO-B) inhibitors. However, we discuss changes in treatment strategies, including dosing and the use of combination therapy used in an attempt to reduce or delay the appearance of motor complications and other adverse events. We will also review several investigational treatments that have shown promise for the treatment of early Parkinson's disease, including a new extended release formulation of carbidopa/levodopa (IPX066), safinamide which inhibits MAO-B, dopamine uptake and glutamate and pardoprunox which is a 5HT-1A agonist and a partial dopamine agonist. Finally, we discuss recent studies focusing on exercise as an important component in the management of early Parkinson's disease.SUMMARYAdvances in the management of early Parkinson's disease include evolving treatment strategies, new investigational treatments, and earlier implementation of various forms of exercise.

31 Dec 2013·Current Medicinal Chemistry

Dual Ligands Targeting Dopamine D2 and Serotonin 5-HT<sub>1A</sub> Receptors as New Antipsychotical or Anti-Parkinsonian Agents

Review

Author: Na Ye ; Ao Zhang ; Zilan Song

Psychiatric disorders like schizophrenia and neurodegenerative diseases like Parkinson's disease are associated with poly-factorial pathogenic mechanisms, with several neurotransmitter systems closely involved. In addition to the cerebral dopaminergic (DA) system, the serotoninergic (5-HT) system also plays a crucial role in regulating psychoemotional, cognitive and motor functions in the central nervous system (CNS). Among the large 5-HT receptor family, accumulating data have revealed new insights into the therapeutic benefit of the 5-HT1A receptor in treating various CNS disorders, especially schizophrenia and Parkinson's disease. The present review discusses the advance of dual agents with mixed actions at the dopamine D2 and serotonin 5-HT1A receptors in the treatment of these diseases. Aripiprazole was the only marketed drug with dual D2 and 5-HT1A profile. It is a partial D2 and 5-HT1A receptor agonist and has been prescribed as an atypical antipsychotical drug. Two other drugs Cariprazine and Pardoprunox are being investigated in clinic. Most of the other candidate compounds, including Bifeprunox, Sarizotan, Mazapertine succinate, PF-217830, and Adoprazine were discontinued due to either non-optimal pharmacokinetic properties or insufficient therapeutical efficacy. Although much effort has been done to highlight the advantages of the 5-HT1A and D2 dual approach, it has to be pointed out that many of these drugs showed poly-pharmacological profile by targeting many other receptors and/or transporters besides the D2 and 5-HT1A receptors. In this regard, 'pure' compounds exclusively acting on the D2 and 5-HT1A receptors are highly needed to further validate this approach. Meanwhile, safety concerns and in vivo pharmacokinetic alerts should also be implanted to the drug design art early.

100 Deals associated with Pardoprunox Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09366	Pardoprunox Hydrochloride	-	DB12061

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Parkinson Disease	Phase 3	-	Solvay SA	-
Parkinson Disease	Phase 3	-	Solvay SA	-
Parkinson Disease	Phase 3	-	Solvay SA	-
Parkinson Disease	Phase 3	-	AbbVie, Inc.	-
Parkinson Disease	Phase 3	-	Solvay SA	-
Parkinson Disease	Phase 3	ZA	Solvay SA	-
Parkinson Disease	Phase 3	-	AbbVie, Inc.	-
Parkinson Disease	Phase 3	ZA	Solvay SA	-
Parkinson Disease	Phase 3	-	Solvay SA	-
Parkinson Disease	Discovery	-	Solvay SA	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00406588 (Pubmed \| Parkinsonism Relat Disord)	Phase 3	Parkinson Disease	295	Pardoprunox	(jwplgtqied) = ytgcoatqvg lnnzwwxxmj (sriltwutcm )	-	01 May 2012
				Placebo	(jwplgtqied) = wablveajlx lnnzwwxxmj (sriltwutcm )